In a groundbreaking advancement in the fight against one of humanity’s oldest and deadliest foes, researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have unveiled a novel therapeutic DNA vaccine designed to combat tuberculosis (TB). Detailed in a recent publication in the Journal of Clinical Investigation, this innovative vaccine leverages intranasal delivery and a genetic fusion strategy to target the elusive drug-tolerant bacterial subpopulation known as “persisters,” which notoriously evade conventional antibiotic regimens, fostering disease relapse and drug resistance.
Tuberculosis, a scourge that has haunted humankind for millennia, remains a global health crisis. The World Health Organization estimates that roughly one-quarter of the world’s population—about two billion people—harbor latent TB infections, which are asymptomatic but can reactivate. In 2024 alone, TB claimed over 1.2 million lives globally and afflicted more than 10 million individuals with active disease, cementing its place as the leading cause of death from a single infectious agent. Despite the availability of antibiotic treatments, TB’s persistence and emerging drug-resistant strains continue to challenge control efforts worldwide.
Contemporary treatment strategies often require prolonged multidrug regimens, which patients struggle to complete due to side effects, logistical challenges, and adherence issues. This incomplete treatment fuels drug resistance and relapse. Recognizing these challenges, the World Health Organization has advocated for adjunctive therapeutic vaccines that can enhance drug efficacy, shorten treatment courses, and improve patient outcomes. The Johns Hopkins team’s nose-delivered DNA vaccine stands out as a promising candidate to fulfill this pivotal role in TB management.
At the core of this vaccine’s unique mechanism is the fusion of two genes, relMtb and Mip3α, capitalizing on the biology of TB bacteria and host immune response pathways. The relMtb gene encodes a protein critical for bacterial survival under stress, including antibiotic assault, by inducing a persistent state that enables drug tolerance. By incorporating this gene’s product into the vaccine, the immune system is primed to recognize and target these otherwise resilient persister bacteria.
Complementing relMtb’s targeting role, the Mip3α gene fused within this construct acts as a powerful immunological beacon. It attracts immature dendritic cells—the body’s sentinels responsible for antigen capture and presentation to T cells, the architects of adaptive immunity. Through this targeted recruitment, the vaccine ensures a more efficient initiation of the immune cascade necessary to develop robust cellular responses against TB.
The choice of intranasal delivery is strategically aligned with the pathogenesis of tuberculosis, which primarily infects the respiratory tract. By administering the vaccine through the nasal mucosa, the researchers direct immune activation to the critical entry points of infection—the lungs and airway mucosa. This mode of delivery promotes the generation of durable localized T-cell immunity, with systemic immune activation as an additional benefit, enhancing the overall protective landscape.
Preclinical studies in mice demonstrated that co-administration of this DNA fusion vaccine with first-line TB drug therapy accelerated bacterial clearance from the lungs, mitigated lung inflammation, and crucially, prevented disease relapse following treatment cessation. This integrated approach exhibited synergy with potent drug combinations, including bedaquiline, pretomanid, and linezolid, which are pivotal in combating drug-resistant TB forms. Such findings underscore the vaccine’s potential as an adjunct therapy against recalcitrant TB cases.
At the cellular level, vaccination led to enhanced recruitment and activation of dendritic cells in the lungs. These activated antigen-presenting cells improved spatial organization with T cells within pulmonary tissue, a hallmark of effective immune orchestration. The immune response encompassed both CD4+ helper T cells and CD8+ cytotoxic T cells, which together mediate comprehensive antimicrobial activity through cytokine production and direct killing of infected cells.
Augmenting these observations, studies in rhesus macaques—a model with immunological characteristics more closely resembling humans—revealed that the vaccine elicited measurable TB-specific immune responses not only in the airways but also in peripheral blood. Remarkably, these responses persisted for at least six months post-vaccination, suggesting long-lasting immunity. However, it is critical to note that these primate studies evaluated immune activation without challenging the animals with active TB infection, thereby focusing on immunogenicity rather than direct efficacy.
Despite the encouraging data, the researchers emphasize that extensive additional preclinical investigations are essential before considering human clinical trials. Promising immune activation in primates provides a vital translational link between murine efficacy models and upcoming studies validating safety, dosing, and effectiveness in humans.
The broader implications of this research extend beyond a single vaccine candidate. Targeting TB persisters through immunotherapy represents a strategic paradigm shift in disease control, moving away from reliance solely on antimicrobial drugs toward empowering the host immune system to eradicate latent and resilient bacterial populations. This multipronged attack may play a critical role in circumventing the growing threat of antibiotic resistance.
Furthermore, DNA vaccines offer several practical advantages in the context of global TB control. Their inherent stability facilitates storage and transport in resource-limited settings, while their relatively straightforward and scalable manufacturing processes could enable widespread deployment. If successful in human trials, this therapeutic vaccine could address critical gaps in TB treatment, particularly for vulnerable populations contending with drug-resistant strains or those struggling with lengthy antibiotic regimens.
The research ensemble at Johns Hopkins includes a multidisciplinary team whose expertise spans molecular biology, immunology, infectious diseases, and pharmacology. This collective effort underscores the collaborative spirit driving innovations in TB therapeutics. Importantly, some team members are listed as inventors on a related patent for the Mip3α/relMtb vaccine, highlighting the novelty and potential commercial and clinical value of this approach.
Funding acknowledgments reflect significant support from prominent institutions and foundations, including the National Institutes of Health and various Johns Hopkins University awards, underscoring the critical role of sustained financial investment in tackling global health challenges like tuberculosis.
As the world grapples with the persistent burden of TB and the rising tide of drug resistance, this novel intranasal DNA vaccine embodies a beacon of hope. Through targeted immunological interventions designed to disarm the bacterial persisters, the Johns Hopkins vaccine strategy could pave the way for transformative advances in TB therapy, heralding a new era of combined immunotherapeutic and antimicrobial treatments that save lives and curb the spread of this ancient and formidable disease.
Subject of Research: Development of a therapeutic intranasal DNA vaccine targeting drug-tolerant Mycobacterium tuberculosis persisters.
Article Title: [Not Provided]
News Publication Date: [Not Provided]
Web References: https://doi.org/10.1172/jci196648
References: Included in the Johns Hopkins Medicine publication.
Image Credits: Not Provided.
Keywords: Tuberculosis, DNA vaccine, intranasal delivery, drug-resistant TB, persister bacteria, immune response, dendritic cells, T-cell immunity, therapeutic vaccine, Mycobacterium tuberculosis, bedaquiline, pretomanid, linezolid
